Showing results (191-200 of 218) with videos related to
Sort By:
Pageof 22
Cell|October 16, 2020
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder CancerPatrick A Ott, Siwen Hu-Lieskovan, Bartosz Chmielowski, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 27, 2022
Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung CancerSemanti Mukherjee, Chaitanya Bandlamudi, Matthew D Hellmann, et al.The New England Journal of Medicine|April 17, 2018
Neoadjuvant PD-1 Blockade in Resectable Lung CancerPatrick M Forde, Jamie E Chaft, Kellie N Smith, et al.Cancer Research|December 14, 2018
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung CancerValsamo Anagnostou, Patrick M Forde, James R White, et al.Cancer Immunology Research|April 16, 2017
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLCPaul C Tumeh, Matthew D Hellmann, Omid Hamid, et al.Science (New York, N.Y.)|March 5, 2016
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockadeNicholas McGranahan, Andrew J S Furness, Rachel Rosenthal, et al.Immunity|December 27, 2022
The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancerAndrew Chow, Fathema Z Uddin, Michael Liu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2021
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 TrialLuis G Paz-Ares, Suresh S Ramalingam, Tudor-Eliade Ciuleanu, et al.Cancer Discovery|March 25, 2017
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging TherapiesEmmet J Jordan, Hyunjae R Kim, Maria E Arcila, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2020
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLCMatthew D Hellmann, Barzin Y Nabet, Hira Rizvi, et al.Pageof 22